Diabetic Retinopathy (DR)
Conditions
Keywords
Diabetic Retinopathy, Prospective cohort, Multimodal biomarker
Brief summary
The goal of this observational study is to enroll diabetic patients with diabetic retinopathy and those without diabetic retinopathy, follow up and observe the long-term changes in ocular structure and function of the subjects by comparison, analyze their association with multimodal biomarkers, and explore new methods for the early diagnosis and risk prediction of diabetic retinopathy. Participants will be followed up over a 5-year follow-up period, during which they will undergo ophthalmic examinations, blood tests, and questionnaires.
Interventions
None listed
Sponsors
Zhongshan Ophthalmic Center, Sun Yat-sen University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* Participants must understand the clinical trial, voluntarily participate, and sign the informed consent form. * Aged 18-80 years, with no restriction on gender. * Healthy control group: No history or diagnosis of diabetes. * Diabetic group: i) Definite diagnosis of diabetes. Both type 1 and type 2 diabetic patients will be included in this study. ii) Based on dilated fundus examination, subjects are classified into NDR, NPDR, and PDR groups according to the staging of diabetic retinopathy. * Idiopathic epiretinal membrane (iERM) group is set as the control group for intraocular specimen collection and analysis in PDR patients: Funduscopic examination shows gold foil-like reflection or glass membrane-like substance covering the macular area, causing local retinal folds, with or without tortuosity and deformation of small perimacular blood vessels; OCT examination reveals a hyperreflective band on the retinal surface of the macular area; meeting the indications for pars plana vitrectomy combined with internal limiting membrane-epiretinal membrane peeling: visual acuity \< 0.3, or visual acuity \> 0.5 but accompanied by progressive vision loss, severe metamorphopsia, diplopia, visual field defect, or other symptoms that significantly affect quality of life, and surgical treatment can be performed if actively requested by the patient; no diagnosis or history of diabetes.
Exclusion criteria
* Complicated with other severe ocular diseases (e.g., glaucoma, age-related macular degeneration, uveitis, etc.). * A history of previous ocular surgery. * Complicated with severe systemic diseases (e.g., ischemic heart disease, stroke, malignant tumor, and severe liver or kidney diseases) or a history of systemic surgery (e.g., coronary artery bypass grafting, arterial/venous thrombolysis, organ transplantation, etc.). * Complicated with cognitive impairment (MMSE score \< 24), mental illness (e.g., schizophrenia, bipolar disorder), or inability to cooperate with questionnaires and ophthalmic examinations due to language comprehension deficits.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The progression of diabetic retinopathy during the follow-up period. | From baseline to study completion, an average of 5 years. |
Secondary
| Measure | Time frame |
|---|---|
| Changes in ocular functional indicators during the follow-up period. | From baseline to study completion, an average of 5 years. |
| Changes in ocular fundus structure during follow-up as indicated by optical coherence tomography (OCT) examination. | From baseline to study completion, an average of 5 years. |
| Changes in best-corrected visual acuity during the follow-up period. | From baseline to study completion, an average of 5 years. |
| Blood and intraocular fluid metabolite concentrations measured by metabolomics during follow-up. | From baseline to study completion, an average of 5 years. |
| Blood and intraocular fluid protein concentrations measured by proteomics during follow-up. | From baseline to study completion, an average of 5 years. |
| Changes in ocular fundus blood flow during follow-up by optical coherence as indicated by tomography angiography (OCTA) examination. | From baseline to study completion, an average of 5 years. |
Countries
China
Contacts
Primary ContactLi Tao, MD, PhD
Backup ContactKangjie Kong, MD, PhD
Outcome results
None listed